MSD Global Health Innovation Fund
One Merck Drive, Whitehouse Station, NJ, 08889, United States
Overview
Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions. Merck GHI has $500M under management and provides growth capital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck. With a vision that data will be the currency in healthcare, GHI invests broadly in digital health. GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation. Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 7
Sector focus
- Finance
- Health Care
- Venture Capital
Investment portfolio
- Turbine
Participated · Series B · Feb 2026
Turbine’s core product is a foundational virtual cell model that, together with a lab-in-the-loop data engine, creates digital twins of wet-lab assays. Researchers use these virtual assays through Turbine’s no-code Virtual Lab to run millions of in-silico experiments, identifying disease drivers and optimal therapeutic combinations far faster than physical labs allow. The platform has already supported more than 30 discovery programs for biopharma partners such as MSD (Merck & Co.), AstraZeneca and Bayer. Previously focused on oncology, the company is now expanding into immunology via a newly announced collaboration with an unnamed top-10 pharmaceutical firm that will supply proprietary immune-cell datasets. The fresh capital will fund the virtualization of additional assay types across discovery and translational medicine, further fine-tuning the platform to new tissues. Turbine is backed by prominent tech and life-sciences investors including Accel and MSD Global Health Innovation and operates from hubs in London and Budapest.